Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Waters Corporation is merging with Becton, Dickinson and Company (BD) to form a $17.5 billion company that will double its market to $40 billion, with projected sales of $6.5 billion by 2025. Neurocrine Biosciences, Inc. reported positive outcomes for adults treated with CRENESSITY, highlighting challenges faced by patients with classic congenital adrenal hyperplasia.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
